Caas Capital Management LP Adc Therapeutics Sa Transaction History

Caas Capital Management LP

  • $836 Million
  • Q3 2024

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2022

May 13, 2022
SELL
$13.28 - $20.03 $172,082 - $259,548
-12,958 Closed
0 $0
Q4 2021

Feb 14, 2022
BUY
$19.29 - $31.51 $249,959 - $408,306
12,958 New
12,958 $262,000
Q4 2020

Feb 12, 2021
SELL
$25.26 - $38.02 $884,100 - $1.33 Million
-35,000 Closed
0 $0
Q2 2020

Aug 14, 2020
BUY
$29.65 - $46.81 $1.04 Million - $1.64 Million
35,000 New
35,000 $1.64 Million

Others Institutions Holding ADCT

# of Institutions
79
Shares Held
55M
Call Options Held
82.7K
Put Options Held
31.5K
View Full List

About ADC Therapeutics SA

ADCT Quotes by TradingView
  • Ticker ADCT
  • Exchange NYSE
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 77,645,296
  • Market Cap $155M
  • Description
  • ADC Therapeutics SA, a commercial-stage biotechnology company, develops antibody drug conjugates (ADC) for patients suffering from hematological malignancies and solid tumors. Its flagship product ZYNLONTA that is in Phase II clinical trial for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma;...
More about ADCT
Track This Portfolio

Track Caas Capital Management LP Portfolio

Follow Caas Capital Management LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Caas Capital Management LP, based on Form 13F filings with the SEC.

News

Stay updated on Caas Capital Management LP with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email